BR112022011291A2 - Método para formar um conjugado de uma sulfonamida e um polipeptídeo - Google Patents

Método para formar um conjugado de uma sulfonamida e um polipeptídeo

Info

Publication number
BR112022011291A2
BR112022011291A2 BR112022011291A BR112022011291A BR112022011291A2 BR 112022011291 A2 BR112022011291 A2 BR 112022011291A2 BR 112022011291 A BR112022011291 A BR 112022011291A BR 112022011291 A BR112022011291 A BR 112022011291A BR 112022011291 A2 BR112022011291 A2 BR 112022011291A2
Authority
BR
Brazil
Prior art keywords
sulfonamide
polypeptide
conjugate
forming
activated
Prior art date
Application number
BR112022011291A
Other languages
English (en)
Inventor
Boehme Thomas
RAEDISCH Marisa
Gerken Manfred
STEYER Oliver
Boscheinen Oliver
SCHEPS Daniel
Wehlan Hermut
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112022011291A2 publication Critical patent/BR112022011291A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

MÉTODO PARA FORMAR UM CONJUGADO DE UMA SULFONAMIDA E UM POLIPEPTÍDEO. A presente invenção refere-se a um método para formar um conjugado de uma sulfonamida e um polipeptídeo, compreendendo: a) fornecer uma sulfonamida ativada, em que a sulfonamida ativada corresponde à Fórmula (I); b) fornecer uma solução aquosa de um polipeptídeo tendo um grupo amino livre, em que a solução aquosa compreende opcionalmente um álcool; c) colocar a solução aquosa de b) em contato com a sulfonamida ativada de a); e d) reagir a sulfonamida ativada com o polipeptídeo tendo um grupo amino livre, obtendo uma solução compreendendo o conjugado de uma sulfonamida e um polipeptídeo, em que a sulfonamida está ligada covalentemente ao polipeptídeo. Também associados conjugados, processos, procedimentos, pró-insulinas e similares.
BR112022011291A 2019-12-10 2020-12-10 Método para formar um conjugado de uma sulfonamida e um polipeptídeo BR112022011291A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306610 2019-12-10
PCT/EP2020/085415 WO2021116243A1 (en) 2019-12-10 2020-12-10 A method of forming a conjugate of a sulfonamide and a polypeptide

Publications (1)

Publication Number Publication Date
BR112022011291A2 true BR112022011291A2 (pt) 2022-09-06

Family

ID=69174254

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011291A BR112022011291A2 (pt) 2019-12-10 2020-12-10 Método para formar um conjugado de uma sulfonamida e um polipeptídeo

Country Status (11)

Country Link
US (1) US20230346949A1 (pt)
EP (1) EP4073096A1 (pt)
JP (1) JP2023505814A (pt)
KR (1) KR20220112817A (pt)
CN (1) CN114867743A (pt)
AU (1) AU2020399194A1 (pt)
BR (1) BR112022011291A2 (pt)
CA (1) CA3164136A1 (pt)
IL (1) IL293635A (pt)
MX (1) MX2022007034A (pt)
WO (1) WO2021116243A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010425B (zh) 2004-08-13 2010-05-26 霍夫曼-拉罗奇有限公司 多肽的c-末端修饰
KR101304958B1 (ko) 2005-09-14 2013-09-17 에프. 호프만-라 로슈 아게 트립신 변이체에 의한 인슐린 전구체의 절단
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
WO2013086785A1 (zh) * 2011-12-15 2013-06-20 Qin Shulin 具有降血糖作用的化合物、组合物及其用途
CA2890719C (en) * 2012-11-05 2023-02-14 Case Western Reserve University Long-acting single-chain insulin analogues
WO2017032798A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
PL239062B1 (pl) * 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin

Also Published As

Publication number Publication date
EP4073096A1 (en) 2022-10-19
MX2022007034A (es) 2022-06-23
IL293635A (en) 2022-08-01
JP2023505814A (ja) 2023-02-13
KR20220112817A (ko) 2022-08-11
CA3164136A1 (en) 2021-06-17
CN114867743A (zh) 2022-08-05
AU2020399194A1 (en) 2022-07-28
WO2021116243A1 (en) 2021-06-17
US20230346949A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
BR112014031613A2 (pt) processo para preparação de conjugados de anticorpos e conjugados de anticorpos
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BRPI0619357B8 (pt) anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
BR112016000680A2 (pt) conjugado de monômero de polipeptídeo biologicamente ativo e fragmento fc de imunoglobulina com eliminação mediada por receptor reduzida e método para a preparação do mesmo
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BRPI0507856A (pt) composição farmacêutica, e, processo para preparar o anticorpo abeta
BR0312781A (pt) Gel derivado de ácido hialurÈnico e método para preparar o mesmo
BRPI0609278B8 (pt) método para preparar uma composição farmacêutica e composição farmacêutica
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
BR112013008407A2 (pt) antígenos de clostridium difficile
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
BR112013010918B8 (pt) composição compreendendo sal de cloridrato de alumínio, método de fabricação do referido sal e usos do mesmo
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112017010832A2 (pt) composições de aminoácido para o tratamento de sintomas de doença
BR112021016619A2 (pt) Anticorpo capaz de se ligar à calreticulina mutante de forma clivada e agente de diagnóstico, profilático ou terapêutico para neoplasmas mieloproliferativos
PE20081687A1 (es) Proteina de fusion
BR112013030473A2 (pt) meios e métodos para diagnóstico e tratamento de esclerose múltipla